Oncopeptides AB (publ)

SSE:ONCO.ST

7.26 (SEK) • At close February 20, 2024
Bedrijfsnaam Oncopeptides AB (publ)
Symbool ONCO.ST
Munteenheid SEK
Prijs 7.264
Beurswaarde 656,953,465
Dividendpercentage 0%
52-weken bereik 6.21 - 12.4
Industrie Biotechnology
Sector Healthcare
CEO Dr. Jakob Lindberg Med. Lic
Website https://www.oncopeptides.com/sv

An error occurred while fetching data.

Over Oncopeptides AB (publ)

Oncopeptides AB (publ), a biotech company, develops pharmaceuticals drugs for the treatment of cancer in the United States, Europe, and internationally. Its lead product candidate is melflufen, an anti-cancer peptide drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. Oncopeptides AB (publ) was incorporated in 2000

Vergelijkbare Aandelen

FluoGuide A/S logo

FluoGuide A/S

FLUO.ST

55.6 SEK

InDex Pharmaceuticals Holding AB (publ) logo

InDex Pharmaceuticals Holding AB (publ)

INDEX.ST

0.244 SEK

Stille AB logo

Stille AB

STIL.ST

160.5 SEK

Episurf Medical AB (publ) logo

Episurf Medical AB (publ)

EPIS-B.ST

0.98 SEK

Bio-Works Technologies AB (publ) logo

Bio-Works Technologies AB (publ)

BIOWKS.ST

4.85 SEK

Egetis Therapeutics AB (publ) logo

Egetis Therapeutics AB (publ)

EGTX.ST

6.07 SEK

Enzymatica AB (publ) logo

Enzymatica AB (publ)

ENZY.ST

3.05 SEK

Karolinska Development AB (publ) logo

Karolinska Development AB (publ)

KDEV.ST

1.65 SEK

Mendus AB (publ) logo

Mendus AB (publ)

IMMU.ST

0.469 SEK

Financiële Gegevens

Cijfers zijn in miljoenen (SEK)

Cijfers zijn in miljoenen (SEK)